Epidarex Capital is a leading transatlantic venture capital firm that invests in early-stage, high growth life science opportunities in under-ventured markets.  Epidarex funds ground-breaking research, often building companies from scratch, to address large unmet medical needs with solutions that provide significant benefits to patients.

Sirakoss

Confluence Life Sciences

Apellis Pharmaceuticals

Epidarex Capital

Our Chief Medical Officer Catherine (Cass) Kelleher, MD spoke to In Vivo about her role at Mironid, the unmet medical need in ADPKD and the potential impact of our LoAc® small molecule in development for the treatment of ADPKD.
 
Read the full Q&A here: https://lnkd.in/etuv4rz5
 
#KidneyDisease #RareDisease #Biopharma #DrugDevelopment

Congratulations to Epidarex portfolio company Lario Therapeutics on winning the ‘Company Making a Difference Award’ at the CDLK5 Forum. This is an exciting time for Lario Therapeutics and Epidarex Capital.

Epidarex is delighted to support this initiative!

We are delighted that five Epidarex portfolio companies have been showcased among the 50 companies in PwC UK’s 2023 'Life Sciences Future 50' report, illustrating the world-class science and innovation that Epidarex is funding across the UK.

We are delighted to welcome Kevin Lee to the Macomics board!

Great to see that NodThera has commenced a Phase Ib/IIa cardiovascular risk study with their lead brain penetrant NLRP3 inhibitor.

We’re pleased to announce that Matthew Miessau has been promoted to Principal. 

Matthew joined Epidarex as an intern and has been an integral part of the team since the firm’s early days. He has been actively involved in deal sourcing including expanding Epidarex’s reach and relationships with key universities in emerging hubs in the US. He has also focused on conducting due diligence and portfolio management on both sides of the Atlantic. Matthew is a frequent speaker, mentor and instructor acting as an ambassador for Epidarex and a champion of the local ecosystem.

Congratulations Matthew!

Epidarex Venture Partner Terri Burke is delighted to be participating in this week’s MedTech Conference in Anaheim, California.

Congratulations to Apellis Pharmaceuticals on receiving FDA approval of the EMPAVELI® Injector.

Northpond Ventures is a venture capital firm that invests in early-stage life science and healthcare companies.

Northpond Ventures

Early Light Ventures is an investment firm specializing in early-stage life science and health technology companies.

Early Light Ventures

Abingworth LLP is a leading international investment group dedicated to life sciences and healthcare.

Abingworth LLP

Alta Partners is a venture capital firm that invests in life sciences and healthcare companies.

Alta Partners

Seroba Life Sciences Management Ltd is a venture capital firm specializing in life sciences and medical devices.

Seroba Life Sciences Management Ltd

Atlas Venture GmbH is a leading venture capital firm focused on early-stage investments in life sciences and healthcare.

Atlas Venture GmbH

Epidarex Capital is an independent, international, and privately-held investment firm that specializes in early-stage life science and health technology companies. The firm focuses on providing capital and strategic support to companies developing innovative technologies and therapeutics with the potential to transform the future of healthcare.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	May 11, 2024 12:31 PM	801666c7
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 11, 2024 3:59 PM	76ab1b91
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 11, 2024 12:31 PM	4b7059ea
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 11, 2024 12:31 PM	7394260c
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:EPIDAREX

Epidarex Capital